Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079569 | 0.74 | CYP11B2 (0.38) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL844970 | 0.74 | KCNQ2 (0.35) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL14157127 | 0.74 | KCNQ2 (0.35) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL14879606 | 0.74 | LOXL2 (0.48) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL844046 | 0.74 | KCNQ2 (0.35) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| Hydrochloric Acid SCHEMBL18422121 | 0.72 | KCNQ2 (0.34) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL26476245 | 0.69 | KDM4E (0.34) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL14920920 | 0.69 | CYP11B1 (0.40) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL21736827 | 0.67 | CYP11B2 (0.36) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL13615074 | 0.67 | TAAR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | KCNQ2 1050/4885ADRA1D 3447/4885ADRA1A 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.